Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion.

Abstract

Azacitidine is currently the only drug to have shown a significant survival benefit over conventional care regimens in patients with International Prognostic Scoring System (IPSS) intermediate-2 (Int-2) and high-risk myelodysplastic syndromes (MDS), establishing it as an important new treatment for these individuals. However, several aspects of the practical use of azacitidine remain uncertain. This manuscript outlines recommendations discussed by a panel of experts, providing a practical guide for physicians to ensure optimal management of Int-2 and high-risk patients receiving azacitidine.

• Authors: Pierre Fenaux, David Bowen, Norbert Gattermann, Eva Hellström-Lindberg, Wolf-Karsten Hofmann, Michael Pfeilstöcker, Guillermo Sanz, Valeria Santini
• Journal: Leukemia research (Leuk Res) Vol. 34 Issue 11 Pg. 1410-6 (Nov 2010) ISSN: 1873-5835 [Electronic] England
• PMID: 20609474 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: Copyright © 2010 Elsevier Ltd. All rights reserved.

Chemical References

• Antimetabolites, Antineoplastic
• Azacitidine

Topics

• Antimetabolites, Antineoplastic
• Azacitidine (therapeutic use)
• Expert Testimony
• Humans
• Myelodysplastic Syndromes (drug therapy)
• Risk